Related Experiment Video
Updated: Nov 22, 2025

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy
Akihiro Nishiyama1, Yukiko Staub2, Yukio Suga2
1Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; an0510@staff.kanazawa-u.ac.jp.
Background/Aim:
Reportedly, sarcopenia and nutritional status are associated with prognosis in cancer patients. However, data regarding the relationship of these factors with advanced thyroid cancer patients receiving molecular targeted therapy remains scarce. Therefore, we investigated the relationship between nutritional assessment, as well as sarcopenia, and prognosis in patients with advanced thyroid cancer undergoing molecular targeted therapy.
Patients And Methods:
In this retrospective study, sarcopenia and several markers of nutritional status were assessed in advanced thyroid cancer patients at the Kanazawa University Hospital, before the introduction of molecular targeted therapy.
Results:
Advanced thyroid cancer patients with sarcopenia presented a worse prognosis than those without sarcopenia. Additionally, sarcopenia strongly correlated with several markers of nutritional status, such as albumin, prognostic nutrition index, and Glasgow prognostic score.
Conclusion:
Sarcopenia could be a prognostic factor in patients with advanced thyroid cancer receiving molecular targeted therapy.
Related Concept Videos
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

